On Thursday, Bed Bath & Beyond Inc (NASDAQ:BBBY)’s shares dwindled -5.43%, and closed at $73.46, as Bed Bath & Beyond Inc (BBBY), stated financial results for the fourth quarter and full year of fiscal 2014 ended February 28, 2015.
Fiscal 2014 Fourth Quarter and Full Year Results:
For the fourth quarter of fiscal 2014, the Corporation stated net earnings of $1.80 per diluted share ($321.1 million) contrast with net earnings for the fourth quarter of fiscal 2013 of $1.60 per diluted share ($333.3 million). Net sales for the fourth quarter of fiscal 2014 were about $3.337 billion, a raise of about 4.2% from net sales of about $3.203 billion stated in the fourth quarter of fiscal 2013. Comparable sales in the fourth quarter of fiscal 2014 raised by about 3.7%, contrast with an raise of about 1.7% in last year’s fiscal fourth quarter. Comparable sales for the fourth quarter of fiscal 2014 comprise an approximate 0.2% unfavorable influence from the change in the Canadian currency exchange rate.
Bed Bath & Beyond Inc., together with its auxiliaries, operates a chain of retail stores. It sells a range of domestic merchandise, counting bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and certain juvenile products.
McEwen Mining Inc (NYSE:MUX)’s shares dropped -5.00%, and settled at $0.950, during the last trading session on Thursday, after McEwen Mining Inc (MUX), is extremely disdesignated to report an armed robbery occurred recently at our El Gallo 1 mine in Sinaloa, Mexico. An estimated 900 kilograms of gold-bearing concentrate containing about 7,000 ounces of gold were stolen from the refinery. The crime is being vigorously investigated by the Mexican authorities.
The Corporation maintains insurance against these types of incidents and is working closely with its insurance carrier to determine the extent of accessible coverage. However, the Corporation’s policy will not be sufficient to cover the entire predictable loss.
McEwen Mining Inc. explores for, develops, produces, and sells precious and base metals in Argentina, Mexico, and the United States. It primarily explores for gold, silver, and copper. The corporation’s principal assets comprise of a 49% interest in the San José Mine in Santa Cruz, Argentina; the El Gallo 1 mine and El Gallo 2 project in Sinaloa, Mexico; the Gold Bar project in Nevada, the United States; and the Los Azules copper project in San Juan, Argentina.
At the end of Thursday’s trade, Dyax Corp (NASDAQ:DYAX)’s shares dipped -4.79%, and closed at $28.99, after Dyax Corp (DYAX), declared that executive administration will take part in the 14th Annual Needham Healthcare Conference being held April 14-15, 2015 at the Westin Grand Central Hotel in New York City. The Corporation is planned to present on Tuesday, April 14at 11:20am (ET) and will provide a corporate update on DX-2930, the KALBITOR® (ecallantide) business and the Licensing and Funded Research Portfolio (LFRP).
Dyax Corp., a biopharmaceutical corporation, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The corporation distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically.
Biomed Realty Trust Inc (NYSE:BMR), ended its Thursday’s trading session with -4.56% loss, and closed at $21.13,as Biomed Realty Trust Inc (BMR), declared the signing of a 295,000 square foot lease at 675 West Kendall by Alnylam Pharmaceuticals in Cambridge, Massachusetts providing Alnylam with Class A laboratory and office space in the heart of Kendall Square.
Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. This growing life science corporation will occupy all the rentable space accessible on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.
“BioMed Realty has built our business on assisting life science companies be successful by providing the laboratory and office platform for companies like Alnylam to conduct breakthrough science that assist patients throughout the world,” said Bill Kane, Senior Vice President for BioMed Realty. “We will welcome Alnylam to their new home, and provide them our unique real estate expertise to ensure they have the best facility to create life-changing treatments for patients.”
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
